• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients - targeting the target antigen.

作者信息

Uyemura Bradley S, Abid Muhammad Abbas, Suelzer Elizabeth, Abid Muhammad Bilal

机构信息

Medical College of Wisconsin, Milwaukee, WI, USA.

The Aga Khan University Medical College, Karachi, Pakistan.

出版信息

Bone Marrow Transplant. 2022 Nov;57(11):1727-1731. doi: 10.1038/s41409-022-01795-3. Epub 2022 Aug 26.

DOI:10.1038/s41409-022-01795-3
PMID:36028758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9417070/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9177/9417070/1ee13e971e5f/41409_2022_1795_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9177/9417070/1ee13e971e5f/41409_2022_1795_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9177/9417070/1ee13e971e5f/41409_2022_1795_Fig1_HTML.jpg

相似文献

1
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients - targeting the target antigen.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2） 初次和加强疫苗剂量在接受嵌合抗原受体T细胞（CAR-T）治疗的患者中的疗效——针对目标抗原
Bone Marrow Transplant. 2022 Nov;57(11):1727-1731. doi: 10.1038/s41409-022-01795-3. Epub 2022 Aug 26.
2
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.造血干细胞移植和嵌合抗原受体 T 细胞治疗受者对 SARS-CoV-2 疫苗接种的免疫反应。
J Hematol Oncol. 2022 Jun 16;15(1):81. doi: 10.1186/s13045-022-01300-9.
3
Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.接种 COVID-19 疫苗的人面临 SARS-CoV-2 变异体的挑战。
Int J Biol Sci. 2022 Jul 11;18(12):4642-4647. doi: 10.7150/ijbs.72424. eCollection 2022.
4
Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.接种三剂 SARS-CoV-2 mRNA 疫苗的实体器官移植受者与自然感染相比的第四剂后免疫反应。
Viruses. 2022 Oct 19;14(10):2299. doi: 10.3390/v14102299.
5
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.智利科兴疫苗和加强针的血清学研究：抗 SARS-CoV-2 刺突抗体的免疫原性和持久性。
BMC Med. 2022 Jun 9;20(1):216. doi: 10.1186/s12916-022-02406-0.
6
Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster.BNT162b2疫苗加强针接种后有或无SARS-CoV-2感染患者体内的抗SARS-CoV-2 IgG抗体
Infect Dis Now. 2022 Sep;52(6):379-380. doi: 10.1016/j.idnow.2022.06.007. Epub 2022 Jul 6.
7
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.一项在已接种 SARS-CoV-2 疫苗的≥75 岁成年人中评估不同 COVID-19 疫苗免疫原性和反应原性的多国、2 期、随机、自适应方案：在 VACCELERATE 网络内开展的一项试验。
Trials. 2022 Oct 8;23(1):865. doi: 10.1186/s13063-022-06791-y.
8
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于减毒流感病毒载体的鼻内 SARS-CoV-2 疫苗在成年人中的安全性和免疫原性：随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26.
9
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines .CAR-NK 细胞能有效靶向表达 SARS-CoV-2 刺突蛋白的细胞系。
Front Immunol. 2021 Jul 23;12:652223. doi: 10.3389/fimmu.2021.652223. eCollection 2021.
10
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.

引用本文的文献

1
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.曲折之路：COVID-19 时代 CAR-T 及其他新型过继性细胞疗法的传染病考量
Semin Hematol. 2024 Oct;61(5):321-332. doi: 10.1053/j.seminhematol.2024.08.002. Epub 2024 Aug 23.
2
Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections.嵌合抗原受体-T 细胞疗法的病毒问题：潜伏性和偶发性病毒感染。
Curr Opin Infect Dis. 2024 Dec 1;37(6):526-535. doi: 10.1097/QCO.0000000000001066. Epub 2024 Oct 3.
3
Overview of infectious complications among CAR T- cell therapy recipients.

本文引用的文献

1
Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era.COVID-19 时代早期免疫调节剂与 CAR T 细胞免疫疗法
Lancet Oncol. 2022 Jan;23(1):16-18. doi: 10.1016/S1470-2045(21)00695-1.
2
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.造血细胞移植和嵌合抗原受体 T 细胞治疗后对 SARS-CoV-2 疫苗的体液反应的预测因素。
Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov.
3
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group.
CAR-T细胞疗法接受者感染并发症概述。
Front Oncol. 2024 Jul 3;14:1398078. doi: 10.3389/fonc.2024.1398078. eCollection 2024.
4
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.细胞治疗受者中对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗第三和第四剂的免疫反应：系统评价和荟萃分析。
Virol J. 2024 May 3;21(1):103. doi: 10.1186/s12985-024-02375-1.
5
Vaccination of Adults With Cancer: ASCO Guideline.成人癌症患者的疫苗接种：ASCO 指南。
J Clin Oncol. 2024 May 10;42(14):1699-1721. doi: 10.1200/JCO.24.00032. Epub 2024 Mar 18.
6
Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.异基因造血干细胞受者中 SARS-CoV-2 疫苗剂量的疗效：系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2024 Feb 1;25(2):393-399. doi: 10.31557/APJCP.2024.25.2.393.
7
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.COVID-19大流行后时代CAR-T细胞疗法接受者管理的多学科建议。
Exp Hematol Oncol. 2023 Jul 27;12(1):66. doi: 10.1186/s40164-023-00426-x.
8
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.接种疫苗一年后造血干细胞移植和细胞治疗受者的 SARS-CoV-2 反应性抗体衰减、加强效应和突破性 SARS-CoV-2 感染。
Bone Marrow Transplant. 2023 May;58(5):567-580. doi: 10.1038/s41409-023-01946-0. Epub 2023 Feb 28.
9
Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis.CD22特异性和CD19/CD22双特异性嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤患者的疗效和安全性：一项系统评价和荟萃分析
Front Oncol. 2022 Dec 29;12:954345. doi: 10.3389/fonc.2022.954345. eCollection 2022.
接受CAR T细胞疗法治疗B细胞恶性肿瘤的COVID-19患者预后不良：一项代表欧洲血液和骨髓移植学会（EBMT）传染病工作组及欧洲血液学协会（EHA）淋巴瘤小组开展的多中心研究结果
Leukemia. 2021 Dec;35(12):3585-3588. doi: 10.1038/s41375-021-01466-0. Epub 2021 Nov 8.
4
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.异基因造血干细胞移植或基于 CD19 的嵌合抗原受体 T 细胞治疗后患者的 BNT162b2 mRNA COVID-19 疫苗的安全性和免疫原性：一项单中心前瞻性队列研究。
Transplant Cell Ther. 2021 Sep;27(9):788-794. doi: 10.1016/j.jtct.2021.06.024. Epub 2021 Jun 30.
5
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.武汉成人 COVID-19 住院患者严重程度和死亡率的危险因素。
J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12.